Fig. 2

EXOs-LPS (exosomes in SM-LPS supernatant) inhibited OPCs differentiation. A NTA and TEM analyses to detect EXOs/EXOs-LPS particle size and apparent morphology. B Uptake of ExoGlow membrane labeling EXOs/EXOs-LPS by OPCs. C Schematic diagram of co-incubation of OPCs with EXOs/EXOs-LPS. D Immunofluorescence staining of OPCs differentiation after treatment with EXOs/EXOs-LPS, and E, F percentage of PDGFRα⁺ and CNPase⁺ cells. The dosage of EXOs was 2 × 10⁸ particles. G The relative percentage of three differentiation stages of OPCs in each experimental group. H Immunofluorescence staining to determine the expression intensity of MYRF after OPCs treatment with EXOs/EXOs-LPS, and I MYRF fluorescence intensity. Each data point represents the average of at least 4-6 regions of interest analyzed in each well, n ≥ 3 wells per group. All data are represented by mean ± SEM. One-way ANOVA was used to determine P values (E, F, I). **P < 0.01, ***P < 0.001, ****P < 0.0001. Two-way ANOVA was used to determine P values (G). Groups that do not share the same letter are significantly (P < 0.05). One representative of three independent experiments is shown. Scale bar = 100 nm (A), 20 μm (B), and 100 μm (D, H)